glp-1 digital health startups research2guidance GLP-1 Business Report for Healthtech

[25] [26] NICE recommends GLP-1 receptor agonists as second- or third-line therapy for type 2 diabetes when metformin and other oral agents have not achieved adequate control

Baekdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW

The Microdose Protocol specifically uses lower starting doses to minimize these effects while your body adapts to the medication

Rates of diabetic ketoacidosis (DKA) and hypoglycemia were similar between groups

Mechanism of Action 15.5.9

Even within a regulated study, GLP-1 materials should be sourced only from authorized suppliers, with appropriate storage, chain-of-custody records, temperature logs, informed consent language and IRB oversight